Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor TrialVered Stearns, Paul E. Goss, Judith‐Anne W. Chapman et al.|Journal of Clinical Oncology|2014Cited by 43
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast CancerJinani Jayasekera, Thomas B. Julian, George Luta et al.|JNCI Journal of the National Cancer Institute|2018Cited by 35
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast CancerJinani Jayasekera, Yisheng Li, Clyde B. Schechter et al.|JNCI Journal of the National Cancer Institute|2018Cited by 21
Supplementary Figure S6 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N. Ingle, Liewei Wang, Fang Xie et al.|Unknown|2023Cited by 0
Supplementary Figure S3 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N. Ingle, Liewei Wang, Fang Xie et al.|Unknown|2023Cited by 0